Bristol Myers Squibb

Scientists know firsthand the excitement and hope inspired by a potential breakthrough. Our teams continue to push the boundaries of drug discovery and development, from targeted protein degradation and CAR T cell therapy to our application of AI and machine learning. Explore our science through the eyes of our R&D experts: https://bit.ly/4jhxGFw #OneBMS

We are excited to announce our new video series, Trials to Transformation, where our CEO Chris Boerner speaks with leaders to share stories of how moments of challenge and failure can lead to personal and professional transformation and impact. The first episode featuring EVP, Chief Research Officer, Head of Research, Dr. Robert Plenge delves into the pace and power of AI in today’s world. #TrialstoTransformation #OneBMS

Alors que le Mois de sensibilisation au cancer du rein tire à sa fin, #BMSCanada s’engage à apporter des changements significatifs dans le domaine du cancer du rein au Canada.  Nous saluons le précieux travail de Kidney Cancer Canada | Cancer du rein Canada pour la mise en place d’un solide réseau de soutien et la promotion de l’amélioration des soins aux patients. Nous partageons la vision de Cancer du rein Canada s’articulant autour d’un contexte plus prometteur pour les personnes touchées par le cancer du rein. 

We’re working to reimagine the patient experience by providing a continuum of care in #Alzheimers disease. Our focus includes researching investigational medicines that may slow or stop progression to those that better manage symptoms, addressing both sides of Alzheimer’s disease with distinct scientific approaches. Explore more about how we’re pursuing the next generation of treatment options through an agile, dual approach: https://bit.ly/4cdB6GY #ADPD2025 #OneBMS

Our scientists are collaborating with Johnson & Johnson Innovative Medicine to find new ways to improve the risk-benefit profile in treatment of thrombotic events for more patients. Together, our combined dedication to advance cardiovascular care continues to power our Phase 3 Librexia program. As we join our industry peers at #ACC25, our Factor XIa research is a key focus. Learn more about our efforts: https://bit.ly/41Yz7Tz

At #SIRS2025, we’re presenting our latest findings in #schizophrenia research. Explore how we are developing innovative treatments to address the complex needs of people living with serious mental health conditions. This is part of our ongoing commitment to advancing research in #neuroscience. Learn more: https://bit.ly/4iSLWoq #OneBMS

“We need to learn to be a future-ready workforce.” See memorable moments from our immersive #WomensHistoryMonth Keynote Session, including a conversation about building resilience and high-performing teams in the age of AI, hosted by the BMS Network of Women (B-NOW) Global Lead Carla Daily with Lynelle Hoch, President, Cell Therapy Organization, Sydney Klein, Chief Information Security Officer, and Amanda Poole, Chief People Officer, plus a keynote by teamwork expert Erica Dhawan. Join us in celebrating our female colleagues who are fueling innovation for patients and our allies who foster a supportive and empowering environment for all women at BMS. #OneBMS

With a 70-year legacy in #CardiovascularDisease (CVD) research, our philosophy has always been to help improve the lives of patients living with cardiovascular conditions. At #ACC25, we’re presenting new real-world and clinical data on our research in symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Explore how we’re working to advance care for those living with CVD: https://bit.ly/43zIdY5

We're looking forward to the ACC Congress and sharing the latest information about clinical data in obstructive hypertrophic cardiomyopathy. Learn more about the HCM disease spectrum: https://bit.ly/4hSAx6p #ACC2025